| KRAS oncogene mutations originated from the guanosine nucleotide and over half of all transversions in lung cancer and colorectal cancer were c.34 G>T and c.35 G>T, respectively. c.35 G>A was the most frequent type of transition in both cancers. | colorectal,lung, |
| [Clinical relevance of the K-ras oncogene in colorectal cancer: experience in a Mexican population]. | colorectal, |
| Binding of RAGE to oncogenic KRAS facilitates hypoxia-inducible factor 1 (HIF1)alpha activation and promotes pancreatic tumor growth under hypoxic conditions. | pancreatic, |
| Expression of ras oncogene p21 protein in early gastric carcinoma and adjacent gastric epithelia. | gastric, |
| ras oncogene p21 expression in hepatocellular carcinoma. | liver, |
| Combining clinicopathological predictors and molecular biomarkers in the oncogenic K-RAS/Ki67/HIF-1alpha pathway to predict survival in resectable pancreatic cancer. | pancreatic, |
| Immunohistochemical analysis of normal and mutated ras oncogene p21 expression in human pulmonary and pleural neoplasms. | neoplasm, |
| Loss of sst2 from pancreatic tissues activates PI3K signaling via AKT, leading to activation of NF-kappaB, amplification of oncogenic KRAS signaling, increased expression of CXCL16, and pancreatic tumor formation. | pancreatic, |
| An inflammatory cue from oncogenic hepatocytes upon induction of kras(V12) expression causes a rapid recruitment of neutrophils to oncogenic liver and the neutrophils play a promoting role in early hepatocarcinogenesis. | liver, |
| KRAS oncogene repression in colon cancer cell lines by G-quadruplex binding indolo[3,2-c]quinolines. | colorectal, |
| Studied the role of PAK1/Crk axis in transduction of the oncogenic KRAS signal in non-small cell lung cancer (NSCLC). | lung, |
| Micro-RNA-155 is induced by K-Ras oncogenic signal and promotes ROS stress in pancreatic cancer. | pancreatic, |
| Targeting KRAS Oncogene in Colon Cancer Cells with 7-Carboxylate Indolo[3,2-b]quinoline Tri-Alkylamine Derivatives. | colorectal, |
| Evidence that synthetic lethality underlies the mutual exclusivity of oncogenic KRAS and EGFR mutations in lung adenocarcinoma. | lung, |
| Positive feedback between oncogenic KRAS and HIF-1alpha confers drug resistance in colorectal cancer. | colorectal, |
| F-fluorodeoxyglucose-positron emission tomography/computed tomography imaging of pancreatic tumors in a transgenic rat model carrying the human oncogene. | pancreatic, |
| KIF5B-RET Fusion gene may coincide oncogenic mutations of EGFR or KRAS gene in lung adenocarcinomas. | lung, |
| Ductal activation of oncogenic KRAS alone induces sarcomatoid phenotype. | sarcoma, |
| KRAS and BRAF oncogenes have roles in colorectal cancer development and therapy resistance [review] | colorectal, |
| Loss of N-cadherin in the context of oncogenic K-ras leads to increased pancreatic intraepithelial neoplasia (PanIN) incidence and progression. | pancreatic, |